S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

$0.17
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.15
$0.19
50-Day Range
$0.13
$0.19
52-Week Range
$0.12
$1.52
Volume
3.27 million shs
Average Volume
584,655 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Sonoma Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,854.3% Upside
$3.25 Price Target
Short Interest
Healthy
0.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Sonoma Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.89) to ($0.45) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.64 out of 5 stars

SNOA stock logo

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.

SNOA Stock Price History

SNOA Stock News Headlines

“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Sonoma Pharmaceuticals Inc SNOA
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
Crude Oil Down 2.5%; Mastercard Posts Upbeat Earnings
macOS Sonoma
See More Headlines
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/08/2024
Today
3/29/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNOA
Employees
9
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$3.25
High Stock Price Target
$3.25
Low Stock Price Target
$3.25
Potential Upside/Downside
+1,854.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-5,150,000.00
Pretax Margin
-41.53%

Debt

Sales & Book Value

Annual Sales
$13.27 million
Book Value
$1.72 per share

Miscellaneous

Free Float
14,171,000
Market Cap
$2.60 million
Optionable
Not Optionable
Beta
1.26

Social Links

Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Ms. Amy M. Trombly (Age 56)
    CEO, President & Director
    Comp: $524.19k
  • Mr. Jerome J. Dvonch (Age 56)
    Interim Chief Financial Officer
    Comp: $281.16k
  • Mr. Bruce Thornton (Age 60)
    COO & Corporate Secretary
    Comp: $448.87k
  • Mr. John Dal Poggetto (Age 52)
    Controller
    Comp: $433.36k

SNOA Stock Analysis - Frequently Asked Questions

Should I buy or sell Sonoma Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sonoma Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNOA shares.
View SNOA analyst ratings
or view top-rated stocks.

What is Sonoma Pharmaceuticals' stock price target for 2024?

1 Wall Street analysts have issued twelve-month price targets for Sonoma Pharmaceuticals' shares. Their SNOA share price targets range from $3.25 to $3.25. On average, they predict the company's share price to reach $3.25 in the next year. This suggests a possible upside of 1,854.3% from the stock's current price.
View analysts price targets for SNOA
or view top-rated stocks among Wall Street analysts.

How have SNOA shares performed in 2024?

Sonoma Pharmaceuticals' stock was trading at $0.1804 on January 1st, 2024. Since then, SNOA stock has decreased by 7.8% and is now trading at $0.1663.
View the best growth stocks for 2024 here
.

When is Sonoma Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 19th 2024.
View our SNOA earnings forecast
.

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) announced its quarterly earnings data on Thursday, February, 8th. The company reported ($0.06) earnings per share for the quarter, topping analysts' consensus estimates of ($0.21) by $0.15. The firm earned $3.14 million during the quarter. Sonoma Pharmaceuticals had a negative net margin of 41.24% and a negative trailing twelve-month return on equity of 58.93%.

What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SNOA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners